FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis

This proof-of-concept study demonstrates the potential of mRNA-based therapies delivering FGF21 and APOA1 in experimental AP. While individual treatments effectively reduced pancreatic injury, the APOA1-FGF21 fusion molecule did not exhibit superior activity. Liver-targeted LNP-mRNA administration may offer a promising approach for treating AP, leveraging endogenous production pathways for therapeutic proteins. Further research is warranted to elucidate the mechanisms underlying their therapeutic efficacy and optimize treatment regimens for clinical translation.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2025-01-27
DOI
https://doi.org/10.1186/s12967-025-06129-7
Citations
4
Primary Topic
Pancreatitis Pathology and Treatment
Type
article
Field-Weighted Citation Impact
8.03

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis

Carlos L. del Rio, María U. Latasa, Nuria Ardaiz, Celia Gomar et al.
4 citations
Journal of Translational Medicine
Pancreatitis Pathology and Treatment
8.03
article

FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis

Carlos L. del Rio, María U. Latasa, Nuria Ardaiz, Celia Gomar, Matías A. Ávila, Jesús Urmán, Amaya López-Pascual, Roberto Escudero Barbero, Paolo G.V. Martini, Anne-Renee Graham, Carmen Berasain, Iker Uriarte, Eva Santamaría, Pedro Berraondo, Antonio Fontanellas, Maite G. Fernández‐Barrena, María Arechederra, Tiffany Palmer, James E. Schultz
article en
4 citations

Abstract

This proof-of-concept study demonstrates the potential of mRNA-based therapies delivering FGF21 and APOA1 in experimental AP. While individual treatments effectively reduced pancreatic injury, the APOA1-FGF21 fusion molecule did not exhibit superior activity. Liver-targeted LNP-mRNA administration may offer a promising approach for treating AP, leveraging endogenous production pathways for therapeutic proteins. Further research is warranted to elucidate the mechanisms underlying their therapeutic efficacy and optimize treatment regimens for clinical translation.

Journal of Translational MedicineVol. 23(1)
Catholic University of Ávila (ES), Moderna Therapeutics (United States) (US), Navarre Institute of Health Research (ES), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Universidad de Navarra (ES)
Ministerio de Ciencia, Innovación y Universidades, Ministerio de Sanidad, Consumo y Bienestar Social, Moderna, European Commission, Fundación Científica Asociación Española Contra el Cáncer, Ministerio de Ciencia e Innovación, Gobierno de Navarra, Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra, Instituto de Salud Carlos III, Agencia Estatal de Investigación, European Social Fund
Good health and well-being
Openalex Percentile: Top 3%
Pancreatitis Pathology and Treatment
8.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.